Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial.

Publication Type:

Journal Article

Source:

The lancet oncology, Volume 15, Issue 9, p.966-74 (2014)

Keywords:

2014, August 2014, Center-Authored Paper, Clinical Research Division, Public Health Sciences Division, Vaccine and Infectious Disease Division

Abstract:

Multicentric Castleman's disease is a rare lymphoproliferative disorder driven by dysregulated production of interleukin 6. No randomised trials have been done to establish the best treatment for the disease. We assessed the safety and efficacy of siltuximab-a chimeric monoclonal antibody against interleukin 6-in HIV-negative patients with multicentric Castleman's disease.